Lymphoma is a type of blood cancer that targets the lymphatic system. This type of cancer impacts the cells that are a part of one's immune system, according to the American Cancer Society. There are ...

Clinical trials provide patients with relapsed or treatment-resistant lymphoma access to emerging therapies, making conversations with providers essential, according to Dr. Jennif ...

ROCHESTER, Minn. — Chemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most common forms: non-Hodgkin and Hodgkin. But alternatives to chemotherapy are ...

Refractory and relapsed DLBCL both present several treatment challenges, but available and upcoming options may help improve outcomes. Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin ...

Radiation therapy (also called radiotherapy) uses high-energy beams or atoms to damage the DNA inside cancer cells. After enough damage, the cells cannot multiply, and they die. Based on your subtype ...

Given the multiple treatment options with high efficacy for disease control, we also present considerations of cumulative doses of therapy, subtle issues regarding trial eligibility and subgroup ...

The goal of follicular lymphoma treatment is to put your disease into remission. That means your symptoms, and signs doctors look for on scans, diminish or disappear. You can stay in remission for ...

Experts look back on the year in the news regarding bispecific antibodies for the treatment of B-cell lymphomas including CLL and SLL. The biggest news of 2023 for patients with lymphoma and provers ...

Recent advances in cancer treatment are transforming the outlook for patients with lymphoma, offering renewed hope where options were once limited. According to Dr. Rahul Bhargava, one of India''s ...

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...

Christina Poh, MD, of City of Hope National Medical Center, highlights the benefit of tafasitamab in improving progression-free survival for heavily pretreated patients with relapsed or refractory ...